CHEN Jie, TIAN Yu, GONG Xi-Ping, DONG Ke-Hui, MO Da-Peng, WANG Yi-Long. Relationship of Serum Inflammatory Factor and Recent Visual Impairment in Idiopathic Intracranial Hypertension[J]. Chinese Journal of Stroke, 2019, 14(10): 993-997.
[1] CORBET J J,SAVINO P J,THOMPSON H S,etal. Visual loss in pseudotumor cerebri. Follow-up of57 patients from five to 41 years and a profile of 14patients with permanent severe visual loss[J]. ArchNeurol,1982,39(8):461-474.[2] WALL M. Sensory visual testing in idiopathicintracranial hypertension:measures sensitive tochange[J]. Neurology,1990,40(12):1859-1864.[3] WALL M,GEORGE D. Idiopathic intracranialhypertension. a prospective study of 50 patients[J].Brain,1991,114(Pt 1A):155-180.[4] FARB R I,VANEK I,SCOTT J N,et al. Idiopathicintracranial hypertension:the prevalence andmorphology of sinovenous stenosis[J]. Neurology,2003,60(9):1418-1424.[5] BRUCE B B,PREECHAWAT P,NEWMAN N J,et al. Racial differences in idiopathic intracranialhypertension[J]. Neurology,2008,70(11):861-867.[6] SIMISTER R,BOWLER J V,WILSON P L,et al.Transverse venous sinus stenosis and intracranialhypertension:evidence for which comes first[J]. JNeurol,2008,255(4):601-603.[7] BRUCE B B,KEDAR S,VAN STAVERN G P,etal. Idiopathic intracranial hypertension in men[J].Neurology,2009,72(4):304-309.[8] BRUCE B B,KEDAR S,VAN STAVERN G P,etal. Atypical idiopathic intracranial hypertension:normal BMI and older patients[J]. Neurology,2010,74(22):1827-1832.[9] NORDIC Idiopathic Intracranial HypertensionStudy Group Writing Committee,WALL M,MCDERMOTT M P,et al. Effect of acetazolamide on visual function in patients with idiopathicintracranial hypertension and mild visual loss:theidiopathic intracranial hypertension treatmenttrial[J]. JAMA,2014,311(16):1641-1651.[10] DINKIN M J,PATSALIDES A. Venous sinusstenting in idiopathic intracranial hypertension:results of a prospective trial[J]. J Neuroophthalmol,2017,37(2):113-121.[11] MARKDY K A,MOLLA S P,JENSEN R H,et al.Understanding idiopathic intracranial hypertension:mechanisms,management,and future directions[J].Lancet Neurol,2016,15(1):78-91.[12] MCCLUSKEY G,DOHERTY-ALLAN R,MCCARRON P,et al. Meta-analysis and systematicreview of population-based epidemiological studiesin idiopathic intracranial hypertension[J]. Eur JNeurol,2018,25(10):1218-1227.[13] THAMBISETTY M,LAVIN P J,NEWMANN J,et al. Fulminant idiopathic intracranialhypertension[J]. Neurology,2007,68(3):229-232.[14] POLLAK L,ZOHAR E,GLOVINSKY Y,et al.The laboratory profile in idiopathic intracranialhypertension[J]. Neurol Sci,2015,36(7):1189-1195.[15] SMITH J L. Whence pseudotumor cerebri?[J]. J ClinNeuroophthalmol,1985,5(1):55-56.[16] 中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志,2011,39(7):579-616.[17] OHMAN E M,BHATT D L,STEG P G,et al. TheREduction of Atherothrombosis for Continued Health(REACH)Registry:an international,prospective,observational investigation in subjects at risk foratherothrombotic events-study design[J/OL]. AmHeart J,2006,151(4):786. e1-e10. https://doi.org/10.1016/j.ahj.2005.11.004.[18] WALL M,KUPERSMITH M J,KIEBURTZ KD,et al. The idiopathic intracranial hypertensiontreatment trial:clinical profile at baseline[J]. JAMANeurol,2014,71(6):693-701.